ArticleFrontiers in pharmacology2022
Effective delivery of osteopontin small interference RNA using exosomes suppresses liver fibrosis
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 22 citations in OpenAlex.
- Host immune network-guided reverse vaccinology approach for prioritizing candidate antigens in Schistosoma japonicum-associated liver fibrosis.PLoS neglected tropical diseases · 2026Article
- Pulmonary responses to polyacrylic acid with and without carboxyl groups following intratracheal instillation in rats.Archives of toxicology · 2026Article
- Hyaluronic acid microneedle patch for transdermal delivery of naringin-loaded PEGylated terpesomes in a rat model of rheumatoid arthritis: Modulation TGF-β1, oxidative stress, and inflammation.International journal of pharmaceutics: X · 2026Article
- Next-Generation Minimally Invasive Anti-Aging Therapy: Incorporation of Resveratrol-Nicotinamide Cerosomes into PLGA Microneedles for Enhanced Skin Permeation.Pharmaceutics · 2026Article
- Extracellular Vesicles in Liver Fibrosis: Pathogenic Messengers, Diagnostic Biomarkers, and Therapeutic Nanovectors.Pharmaceutics · 2026Review
- Experimental Study of YaJieShaBa Antialcoholic Hepatic Fibrosis Through TGF-β1/Smad Signaling Pathway.Mediators of inflammation · 2026Article
- Harnessing Nature for Breast Cancer Management: Effects of Fisetin-Loaded Nigellasomes Embedded in Microneedles Improve Tumor Suppression and Reduce Oxidative Stress.Pharmaceutics · 2025Article
- Cardiometabolic Therapies Shape Non-Coding RNA Landscapes in Cardiovascular Fibrosis.Metabolites · 2025Review
- Cutting-edge insights into liver fibrosis: advanced therapeutic strategies and future perspectives using engineered mesenchymal stem cell-derived exosomes.Drug delivery and translational research · 2025Review
- Extracellular vesicles: emerging therapeutic agents for liver fibrosis.Extracellular vesicles and circulating nucleic acids · 2025Review
- Osteopontin: an indispensable component in common liver, pancreatic, and biliary related disease.Journal of cancer research and clinical oncology · 2024Review
- Novel insights into the role of immunomodulatory extracellular vesicles in the pathogenesis of liver fibrosis.Biomarker research · 2024Review
- Extracellular vesicles-derived ferritin from lipid-induced hepatocytes regulates activation of hepatic stellate cells.Heliyon · 2024Article
- Exosomes target HBV-host interactions to remodel the hepatic immune microenvironment.Journal of nanobiotechnology · 2024Review
- Liver Fibrosis Resolution: From Molecular Mechanisms to Therapeutic Opportunities.International journal of molecular sciences · 2023Review
- Calcitriol attenuates liver fibrosis through hepatitis C virus nonstructural protein 3-transactivated protein 1-mediated TGF β1/Smad3 and NF-κB signaling pathways.World journal of gastroenterology · 2023Article
- Osteopontin as a Biomarker in Chronic Kidney Disease.Biomedicines · 2023Review
- Nanoparticles and cytokine response.Frontiers in bioengineering and biotechnology · 2023Review
- Exosomes in liver fibrosis: The role of modulating hepatic stellate cells and immune cells, and prospects for clinical applications.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.